Respiratory Diseases in Women.

Asthma; Bronchiectasis; COPD; Female; ILD; Respiratory diseases; Sex; Vascular diseases; Women; Humans; Prevalence; Male; Sex Factors; Respiratory Tract Diseases/epidemiology; Respiratory Tract Diseases/therapy; Respiratory Tract Diseases/diagnosis; Respiration Disorders/epidemiology; Respiration Disorders/therapy; Respiration Disorders/diagnosis; Women's Health; Pulmonary and Respiratory Medicine

Abstract :

[en] Respiratory diseases exhibit diverse patterns in prevalence, clinical presentations, and outcomes between men and women. Historically, certain conditions were more prevalent in men, but trends have shifted, highlighting the need to understand sex disparities in respiratory health. Social, environmental, and healthcare changes have reshaped the landscape of respiratory diseases, complicating diagnosis and treatment. Moreover, the underrepresentation of women in clinical trials has limited our understanding of their specific needs. In this review, we explore the sex differences in the prevalence, clinical characteristics, and presentation of respiratory diseases, emphasizing the importance of tailored approaches to diagnosis and management. By recognizing and addressing these disparities, we can advance toward more equitable and effective respiratory healthcare for all individuals.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Han, MeiLan K; University of Michigan, Ann Arbor, MI, USA

Shteinberg, Michal; Pulmonology Institute and Cystic Fibrosis Center, Carmel Medical Center and the Technion-Israel Institute of Technology, the B. Rappaport Faculty of Medicine, Haifa, Israel

Assayag, Deborah; Department of Medicine, McGill University, Montreal, Canada

Schleich, Florence ; Université de Liège - ULiège > Département des Sciences de l'activité physique et de la réadaptation > Physiologie humaine et physiologie de l'effort physique

Pengo, Martino; Istituto Auxologico Italiano IRCCS, Milan, Italy, Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy

Scicluna, Victoria M; University of Michigan, Ann Arbor, MI, USA

Lombardi, Carolina; Istituto Auxologico Italiano IRCCS, Milan, Italy, Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy

Barrecheguren, Miriam; Vall d'Hebron Hospital, Barcelona, Spain, CIBERES, Carlos III Health Institute, Madrid, Spain. Electronic address: miriam.barrecheguren@vallhebron.cat

Jara-Palomares, Luis; Respiratory Department, Virgen del Rocío Hospital and Instituto de Biomedicina, Sevilla, Spain, CIBERES, Carlos III Health Institute, Madrid, Spain

Language :

English

Title :

Respiratory Diseases in Women.

Publication date :

May 2025

Journal title :

Archivos de Bronconeumologia

ISSN :

0300-2896

Publisher :

Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR), Spain

Volume :

Issue :

Pages :

290 - 298

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://api.elsevier.com/content/article/PII:S0300289624004125?httpAccept=text/xml

Funders :

GSK - GlaxoSmithKline
CIHR - Canadian Institutes of Health Research
Boehringer Ingelheim
McGill University
BMS - Bristol-Myers Squibb

Funding text :

DA received grants from Boehringer-Ingleheim, Canadian Institute for Health Research, McGill University, and speakers fees and consulting fees from Hoffman La Roche and Boerhinger Ingelheim.LJP received grants from Leo Pharma and MSD and personal fees from Daichii, Rovi, GlaxoSmithKline, BMS and Johnson and Johnson outside the submitted work. No other conflict of interest declared.

Available on ORBi :

since 23 July 2026

Statistics

Number of views

40 (0 by ULiège)

Number of downloads

28 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Pinkerton, K.E., Harbaugh, M., Han, M.K., Jourdan Le Saux, C., Van Winkle, L.S., Martin, W.J. 2nd, et al. Women and lung disease sex differences and global health disparities. Am J Respir Crit Care Med 192 (2015), 11–16.
World Health Organization. The top 10 causes of death. 2020, Fact sheets, Newsroom https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death [accessed 31.10.23].
Ntritsos, G., Franek, J., Belbasis, L., Christou, M.A., Markozannes, G., Altman, P., et al. Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 13 (2018), 1507–1514.
Adeloye, D., Chua, S., Lee, C., Basquill, C., Papana, A., Theodoratou, E., et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health, 5, 2015 020415.
Han, M.K., Chronic obstructive pulmonary disease in women: a biologically focused review with a systematic search strategy. Int J Chron Obstruct Pulmon Dis 15 (2020), 711–721.
Aryal S, Diaz-Guzman E, Mannino DM. Influence of sex on chronic obstructive pulmonary disease risk and treatment outcomes. Int J Chron Obstruct Pulmon. 2014;9:1145-54.
Hardin, M., Foreman, M., Dransfield, M.T., Hansel, N., Han, M.K., Cho, M.H., et al. Sex-specific features of emphysema among current and former smokers with COPD. Eur Respir J 47 (2016), 104–112.
Sørheim, I.C., Johannessen, A., Gulsvik, A., Bakke, P.S., Silverman, E.K., DeMeo, D.L., Gender differences in COPD: are women more susceptible to smoking effects than men?. Thorax 65 (2010), 480–485.
Martinez, C.H., Raparla, S., Plauschinat, C.A., Giardino, N.D., Rogers, B., Beresford, J., et al. Gender differences in symptoms and care delivery for chronic obstructive pulmonary disease. J Womens Health (Larchmt) 21 (2012), 1267–1274.
Scicluna, V., Han, M., COPD in women: future challenges. Arch Bronconeumol 59 (2023), 3–4.
Ancochea, J., Miravitlles, M., García-Río, F., Muñoz, L., Sánchez, G., Sobradillo, V., et al. Underdiagnosis of chronic obstructive pulmonary disease in women: quantification of the problem, determinants and proposed actions. Arch Bronconeumol 49 (2013), 223–229.
Wan, E.S., Balte, P., Schwartz, J.E., Bhatt, S.P., Cassano, P.A., Couper, D., et al. Association between preserved ratio impaired spirometry and clinical outcomes in US adults. JAMA 326 (2021), 2287–2298.
Agustí, A., Celli, B.R., Criner, G.J., Halpin, D., Anzueto, A., Barnes, P., et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Arch Bronconeumol 59 (2023), 232–248.
Lipson, D.A., Barnhart, F., Brealey, N., Brooks, J., Criner, G.J., Day, N.C., et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 378 (2018), 1671–1680.
Rabe, K.F., Martinez, F.J., Ferguson, G.T., Wang, C., Singh, D., Wedzicha, J.A., et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 383 (2020), 35–48.
Bhatt, S.P., Rabe, K.F., Hanania, N.A., Vogelmeier, C.F., Cole, J., Bafadhel, M., et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med 389 (2023), 205–214.
Kumbhare, S., Pleasants, R., Ohar, J.A., Strange, C., Characteristics and prevalence of asthma/chronic obstructive pulmonary disease overlap in the United States. Ann Am Thorac Soc 13 (2016), 803–810.
Schleich, F.N., Manise, M., Sele, J., Henket, M., Seidel, L., Louis, R., Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med, 26, 2013, 11.
Schleich, F.N., Zanella, D., Stefanuto, P.H., Bessonov, K., Smolinska, A., Dallinga, J.W., et al. Exhaled volatile organic compounds are able to discriminate between neutrophilic and eosinophilic asthma. Am J Respir Crit Care Med 200 (2019), 444–453.
Moore, W.C., Bleecker, E.R., Curran-Everett, D., Erzurum, S.C., Ameredes, B.T., Bacharier, L., et al. Characterization of the severe asthma phenotype by the National Heart Lung, and Blood Institute's Severe Asthma Research Program 1. J Allergy Clin Immunol 119 (2007), 405–413.
Haldar, P., Pavord, I.D., Shaw, D.E., Berry, M.A., Thomas, M., Brightling, C.E., et al. Cluster analysis and clinical asthma phenotypes 1. Am J Respir Crit Care Med 178 (2008), 218–224.
Schleich, F.N., Chevremont, A., Paulus, V., Henket, M., Manise, M., Seidel, L., et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J 44 (2014), 97–108.
Gibbs, C.J., Coutts, I.I., Lock, R., Finnegan, O.C., White, R.J., Premenstrual exacerbation of asthma. Thorax 39 (1984), 833–836.
Eliasson, O., Scherzer, H.H., DeGraff, A.C., Morbidity in asthma in relation to the menstrual cycle. J Allergy Clin Immunol 77 (1986), 87–94.
Oguzulgen, I.K., Turktas, H., Erbas, D., Airway inflammation in premenstrual asthma. J Asthma 39 (2002), 517–522.
Yung, J.A., Fuseini, H., Newcomb, D.C., Hormones, sex, and asthma. Ann Allergy Asthma Immunol 120 (2018), 488–494.
Ambhore, N.S., Kalidhindi, R.S.R., Loganathan, J., Sathish, V., Role of differential estrogen receptor activation in airway hyperreactivity and remodeling in a murine model of asthma. Am J Respir Cell Mol Biol 61 (2019), 469–480.
Kwon, H.L., Triche, E.W., Belanger, K., Bracken, M.B., The epidemiology of asthma during pregnancy: prevalence, diagnosis, and symptoms. Immunol Allergy Clin North Am 26 (2006), 29–62.
Schatz, M., Dombrowski, M.P., Wise, R., Thom, E.A., Landon, M., Mabie, W., et al. Asthma morbidity during pregnancy can be predicted by severity classification. J Allergy Clin Immunol 112 (2003), 283–288.
Barr, R.G., Wentowski, C.C., Grodstein, F., Somers, S.C., Stampfer, M.J., Schwartz, J., et al. Prospective study of postmenopausal hormone use and newly diagnosed asthma and chronic obstructive pulmonary disease. Arch Intern Med 164 (2004), 379–386.
Bulkhi, A.A., Shepard, K.V., Casale, T.B., Cardet, J.C., Elevated testosterone is associated with decreased likelihood of current asthma regardless of sex. J Allergy Clin Immunol Pract 8 (2020), 3029–3035.
Hunninghake, G.M., Soto-Quirós, M.E., Avila, L., Kim, H.P., Lasky-Su, J., Rafaels, N., et al. TSLP polymorphisms are associated with asthma in a sex-specific fashion. Allergy 65 (2010), 1566–1575.
Loisel, D.A., Tan, Z., Tisler, C.J., Evans, M.D., Gangnon, R.E., Jackson, D.J., et al. IFNG genotype and sex interact to influence the risk of childhood asthma. J Allergy Clin Immunol 128 (2011), 524–531.
Patel, R., Solatikia, F., Zhang, H., Wolde, A., Kadalayil, L., Karmaus, W., et al. Sex-specific associations of asthma acquisition with changes in DNA methylation during adolescence. Clin Exp Allergy 51 (2021), 318–328.
Moscato, G., Apfelbacher, C., Brockow, K., Eberle, C., Genuneit, J., Mortz, C.G., et al. Gender and occupational allergy: report from the task force of the EAACI Environmental and Occupational Allergy Interest Group. Allergy 75 (2020), 2753–2763.
Hopkins, R.B., Burke, N., Fell, C., Dion, G., Kolb, M., Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. Eur Respir J 48 (2016), 187–195.
Raghu, G., Chen, S.-Y., Hou, Q., Yeh, W.-S., Collard, H.R., Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years old. Eur Respir J 48 (2016), 179–186.
Raghu, G., Chen, S.Y., Yeh, W.S., Maroni, B., Li, Q., Lee, Y.C., et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. Lancet Respir Med 2 (2014), 566–572.
Strongman, H., Kausar, I., Maher, T.M., Incidence prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK. Adv Ther 35 (2018), 724–736.
Tarride, J.E., Hopkins, R.B., Burke, N., Guertin, J.R., O'Reilly, D., Fell, C.D., et al. Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada. Clinicoecon Outcomes Res 10 (2018), 127–137.
Mooney, J., Chang, E., Lalla, D., Papoyan, E., Raimundo, K., Reddy, S.R., et al. Potential delays in diagnosis of idiopathic pulmonary fibrosis in medicare beneficiaries. Ann Am Thorac Soc 16 (2019), 393–396.
Strange, C., Highland, K.B., Interstitial lung disease in the patient who has connective tissue disease. Clin Chest Med 25 (2004), 549–559 vii.
Chartrand, S., Lee, J.S., Swigris, J.J., Stanchev, L., Fischer, A., Clinical characteristics and natural history of autoimmune forms of interstitial lung disease: a single-center experience. Lung 197 (2019), 709–713.
Gharaee-Kermani, M., Hatano, K., Nozaki, Y., Phan, S.H., Gender-based differences in bleomycin-induced pulmonary fibrosis. Am J Pathol 166 (2005), 1593–1606.
Voltz, J.W., Card, J.W., Carey, M.A., Degraff, L.M., Ferguson, C.D., Flake, G.P., et al. Male sex hormones exacerbate lung function impairment after bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 39 (2008), 45–52.
Guler, S.A., Machahua, C., Geiser, T.K., Kocher, G., Marti, T.M., Tan, B., et al. Dehydroepiandrosterone in fibrotic interstitial lung disease: a translational study. Respir Res, 23, 2022, 149.
Svendsen, T.L., Viskum, K., Hansborg, N., Thorpe, S.M., Nielsen, N.C., Pulmonary lymphangioleiomyomatosis: a case of progesterone receptor positive lymphangioleiomyomatosis treated with medroxyprogesterone, oophorectomy and tamoxifen. Br J Dis Chest 78 (1984), 264–271.
Yockey, C.C., Riepe, R.E., Ryan, K., Pulmonary lymphangioleiomyomatosis complicated by pregnancy. Kans Med 87 (1986), 277–278 93.
Eliasson, A.H., Phillips, Y.Y., Tenholder, M.F., Treatment of lymphangioleiomyomatosis. A meta-analysis. Chest 96 (1989), 1352–1355.
Johnson, S.R., Tattersfield, A.E., Clinical experience of lymphangioleiomyomatosis in the UK. Thorax 55 (2000), 1052–1057.
Borie, R., Renzoni, E., Pulmonary fibrosis associated with telomere-related gene mutations: a complex inheritance. Respirology 26 (2021), 1098–1100.
Calado, R.T., Yewdell, W.T., Wilkerson, K.L., Regal, J.A., Kajigaya, S., Stratakis, C.A., et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood 114 (2009), 2236–2243.
Diaz de Leon, A., Cronkhite, J.T., Katzenstein, A.L., Godwin, J.D., Raghu, G., Glazer, C.S., et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLOS ONE, 5, 2010 e10680.
Cronkhite, J.T., Xing, C., Raghu, G., Chin, K.M., Torres, F., Rosenblatt, R.L., et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 178 (2008), 729–737.
Johnson, J., Greaves, L., Repta, R., Better science with sex and gender. A primer for health research. 2007, Vancouver: Library and Archives Canada Cataloguing in Publication.
Phillips, S.P., Defining and measuring gender: a social determinant of health whose time has come. Int J Equity Health, 4, 2005, 11.
Organization WH. Gender, women, and the tobacco epidemic 2010 [cited 14 Dec 2023]. Available from: https://www.who.int/publications/i/item/9789240004849.
Iwai, K., Mori, T., Yamada, N., Yamaguchi, M., Hosoda, Y., Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med 150 (1994), 670–675.
Baumgartner, K.B., Samet, J.M., Stidley, C.A., Colby, T.V., Waldron, J.A., Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 155 (1997), 242–248.
Brigham, E., Allbright, K., Harris, D., Health disparities in environmental and occupational lung disease. Clin Chest Med 41 (2020), 623–639.
Poinen-Rughooputh, S., Rughooputh, M.S., Guo, Y., Lai, H., Sun, W., Chen, W., Sex-related differences in the risk of silicosis among Chinese pottery workers: a cohort study. J Occup Environ Med 63 (2021), 74–79.
Fazzo, L., Cernigliaro, A., De Santis, M., Quattrone, G., Bruno, C., Zona, A., et al. Occupational cohort study of asbestos-cement workers in a contaminated site in Sicily (Italy). Epidemiol Prev 44 (2020), 137–144.
Blanc, P.D., Eisner, M.D., Balmes, J.R., Trupin, L., Yelin, E.H., Katz, P.P., Exposure to vapors, gas, dust, or fumes: assessment by a single survey item compared to a detailed exposure battery and a job exposure matrix. Am J Ind Med 48 (2005), 110–117.
Ferrara, G., Arnheim-Dahlström, L., Bartley, K., Janson, C., Kirchgässler, K.U., Levine, A., et al. Epidemiology of pulmonary fibrosis: a cohort study using healthcare data in Sweden. Pulm Ther 5 (2019), 55–68.
Assayag, D., Lubin, M., Lee, J.S., King, T.E., Collard, H.R., Ryerson, C.J., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Respirology 19 (2014), 493–500.
Winstone, T.A., Assayag, D., Wilcox, P.G., Dunne, J.V., Hague, C.J., Leipsic, J., et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 146 (2014), 422–436.
Ley, B., Ryerson, C.J., Vittinghoff, E., Ryu, J.H., Tomassetti, S., Lee, J.S., et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156 (2012), 684–691.
Morisset, J., Vittinghoff, E., Lee, B.Y., Tonelli, R., Hu, X., Elicker, B.M., et al. The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease. Respir Med 127 (2017), 51–56.
Ryerson, C.J., Vittinghoff, E., Ley, B., Lee, J.S., Mooney, J.J., Jones, K.D., et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. CHEST J 145 (2014), 723–728.
Wälscher, J., Witt, S., Schwarzkopf, L., Kreuter, M., Hospitalisation patterns of patients with interstitial lung disease in the light of comorbidities and medical treatment – a German claims data analysis. Respir Res, 21, 2020, 73.
Dempsey, T.M., Payne, S., Sangaralingham, L., Yao, X., Shah, N.D., Limper, A.H., Adoption of the antifibrotic medications pirfenidone and nintedanib for patients with idiopathic pulmonary fibrosis. Ann Am Thorac Soc 18 (2021), 1121–1128.
Assayag, D., Garlick, K., Johannson, K.A., Fell, C.D., Kolb, M., Cox, G., et al. Treatment initiation in patients with interstitial lung disease in Canada. Ann Am Thorac Soc 18 (2021), 1661–1668.
Sesé, L., Nunes, H., Cottin, V., Israel-Biet, D., Crestani, B., Guillot-Dudoret, S., et al. Gender differences in idiopathic pulmonary fibrosis: are men and women equal?. Front Med (Lausanne), 8, 2021, 713698.
Garvey, J.F., Pengo, M.F., Drakatos, P., Kent, B.D., Epidemiological aspects of obstructive sleep apnea. J Thorac Dis 7 (2015), 920–929.
Campos-Rodriguez, F., et al. Role of sleep apnea and continuous positive airway pressure therapy in the incidence of stroke or coronary heart disease in women. Am J Respir Crit Care Med 189 (2014), 1544–1550.
Pengo, M.F., Won, C.H., Bourjeily, G., Sleep in women across the life span. Chest 154 (2018), 196–206.
Popovic, R.M., White, D.P., Upper airway muscle activity in normal women: influence of hormonal status. J Appl Physiol 84 (1998), 1055–1062.
Laouafa, S., Ribon-Demars, A., Marcouiller, F., Estradiol protects against cardiorespiratory dysfunctions and oxidative stress in intermittent hypoxia. Sleep, 40(8), 2017.
Sands, S.A., Alex, R.M., Mann, D., Vena, D., Terrill, P.I., Gell, L.K., et al. Pathophysiology underlying demographic and obesity determinants of sleep apnea severity. Ann Am Thorac Soc 20 (2023), 440–449.
Young, T., Evans, L., Finn, L., Palta, M., Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep 20 (1997), 705–706.
Redline, S., Kump, K., Tishler, P.V., Browner, I., Ferrette, V., Gender differences in sleep disordered breathing in a community-based sample. Am J Respir Crit Care Med 149 (1994), 722–726.
Pengo, M.F., Rossi, G.P., Steier, J., Obstructive sleep apnea, gestational hypertension and preeclampsia: a review of the literature. Curr Opin Pulm Med 20 (2014), 588–594.
Bourjeily, G., Danilack, V.A., Bublitz, M.H., Obstructive sleep apnea in pregnancy is associated with adverse maternal outcomes: a national cohort. Sleep Med 38 (2017), 50–57.
Perger, E., Mattaliano, P., Lombardi, C., Menopause and sleep apnea. Maturitas 124 (2019), 35–38.
Lindberg, E., Bonsignore, M.R., Polo-Kantola, P., Role of menopause and hormone replacement therapy in sleep-disordered breathing. Sleep Med Rev, 49, 2020, 101225.
Quint, J.K., Millett, E.R.C., Joshi, M., Navaratnam, V., Thomas, S.L., Hurst, J.R., et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J 47 (2016), 186–193.
Snell, N., Gibson, J., Jarrold, I., Quint, J.K., Epidemiology of bronchiectasis in the UK: findings from the British lung foundation's “Respiratory health of the nation” project. Respir Med 158 (2019), 21–23.
Choi, H., Yang, B., Nam, H., Kyoung, D.-S., Sim, Y.S., Park, H.Y., et al. Population-based prevalence of bronchiectasis and associated comorbidities in South Korea. Eur Respir J, 54, 2019 1900194.
Weycker, D., Hansen, G.L., Seifer, F.D., Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. Chron Respir Dis 14 (2017), 377–384.
Chalmers, J.D., Polverino, E., Crichton, M.L., Ringshausen, F.C., De Soyza, A., Vendrell, M., et al. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC). Lancet Respir Med 11 (2023), 637–649.
Aksamit, T.R., O'Donnell, A.E., Barker, A., Olivier, K.N., Winthrop, K.L., Daniels, M.L.A., et al. Adult patients with bronchiectasis: a first look at the US bronchiectasis research registry. Chest 151 (2017), 982–992.
Shoemark, A., Polverino, E., Blasi, F., Ringshausen, F.C., De Soyza, A., Vendrell, M., et al. Characteristics and outcomes of adults with primary ciliary dyskinesia (PCD): an EMBARC/BEAT-PCD analysis Respiratory infections and bronchiectasis. Eur Respir Soc, 2021, PA2062.
Dhar, R., Singh, S., Talwar, D., Mohan, M., Tripathi, S.K., Swarnakar, R., et al. Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. Lancet Glob Health 7 (2019), e1269–e1279.
Dhar, R., Singh, S., Talwar, D., Murali Mohan, B.V., Tripathi, S.K., Swarnakar, R., et al. Clinical outcomes of bronchiectasis in India: data from the EMBARC/Respiratory Research Network of India registry. Eur Respir J, 61, 2023, 2200611.
Finch, S., Polverino, E., Blasi, F., Ringshausen, F., De Soyza, A., Vendrell, M., et al. Sex differences in bronchiectasis patient characteristics: an analysis of the EMBARC cohort, epidemiology. Eur Respir Soc, 2018, PA2282.
Singleton, R.J., Valery, P.C., Morris, P., Byrnes, C.A., Grimwood, K., Redding, G., et al. Indigenous children from three countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. Pediatr Pulmonol 49 (2014), 189–200.
Martínez-García, M.Á., Soler-Cataluña, J.J., Donat Sanz, Y., Catalán Serra, P., Agramunt Lerma, M., Ballestín Vicente, J., et al. Factors associated with bronchiectasis in patients with COPD. Chest 140 (2011), 1130–1137.
Huang, J.T.-J., Cant, E., Keir, H.R., Barton, A.K., Kuzmanova, E., Shuttleworth, M., et al. Endotyping Chronic Obstructive Pulmonary Disease Bronchiectasis, and the “Chronic Obstructive Pulmonary Disease-Bronchiectasis Association”. Am J Respir Crit Care Med 206 (2022), 417–426.
Gatheral, T., Kumar, N., Sansom, B., Lai, D., Nair, A., Vlahos, J., et al. COPD-related bronchiectasis; independent impact on disease course and outcomes. COPD 11 (2014), 605–614.
Shi, L., Wei, F., Ma, T., Zhou, W., Li, M., Wan, Y., Impact of radiographic bronchiectasis in COPD. Respir Care 65 (2020), 1571–1573.
Kumar, K., Loebinger, M.R., Nontuberculous mycobacterial pulmonary disease: clinical epidemiologic features, risk factors, and diagnosis: the nontuberculous mycobacterial series. Chest 161 (2022), 637–646.
McDonnell, M.J., Ahmed, M., Das, J., O'Mahony, M., Breen, D., O'Regan, A., et al. Patterns of disease in patients with middle-lobe predominant bronchiectasis. Respiration 93 (2017 20), 406–414.
Chotirmall, S.H., Smith, S.G., Gunaratnam, C., Cosgrove, S., Dimitrov, B.D., O'Neill, S.J., et al. Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis. N Engl J Med 366 (2012), 1978–1986.
Klein, S.L., Flanagan, K.L., Sex differences in immune responses. Nat Rev Immunol 16 (2016), 626–638.
Prys-Picard, C.O., Niven, R., Urinary incontinence in patients with bronchiectasis. Eur Respir J 27 (2006), 866–867.
Rees, J., Tedd, H., De Soyza, A., Managing urinary incontinence in adults with bronchiectasis. Br J Nurs 22 (2013), S15–S16 S18.
Duignan, N., McDonnell, M.J., Mokoka, M.C., Rutherford, R.M., High prevalence of stress urinary incontinence in adult patients with bronchiectasis. Ir Med J, 109, 2016, 440.
Afzelius, B.A., Eliasson, R., Male and female infertility problems in the immotile-cilia syndrome. Eur J Respir Dis Suppl 127 (1983), 144–147.
Raidt, J., Werner, C., Menchen, T., Dougherty, G.W., Olbrich, H., Loges, N.T., et al. Ciliary function and motor protein composition of human fallopian tubes. Hum Reprod 30 (2015), 2871–2880.
Börekçi, Ş., Kubat, B., Senkardesler, G., Musellim, B., Maternal and fetal problems in patients with non-cystic fibrosis bronchiectasis during pregnancy. Turk Thorac J 22 (2021), 297–300.
Middleton, P.G., Gade, E.J., Aguilera, C., MacKillop, L., Button, B.M., Coleman, C., et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J, 55, 2020, 1901208.
Chowdhury, N.U., Guntur, V.P., Newcomb, D.C., Wechsler, M.E., Sex and gender in asthma. Eur Respir Rev, 30, 2021, 210067.
Peppard, P.E., Young, T., Barnet, J.H., Palta, M., Hagen, E.W., Hla, K.M., Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 177 (2013), 1006–1014.
Konstantinides, S.V., Meyer, G., Bueno, H., Galié, N., Gibbs, J.S.R., Ageno, W., et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J 41 (2020), 543–603.
Konstantinides, S.V., Meyer, G., Galié, N., Simon, R., Gibbs, J., Aboyans, V., et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Respir J 41 (2019), 543–603.
Silverstein, M.D., Heit, J.A., Mohr, D.N., Petterson, T.M., O'Fallon, W.M., Melton, L.J., Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158 (1998), 585–593.
Kearon, C., Ageno, W., Cannegieter, S.C., Cosmi, B., Geersing, G.J., Kyrle, P.A., Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 14 (2016), 1480–1483.
Stevens, S.M., Woller, S.C., Baumann Kreuziger, L., Bounameaux, H., Doerschug, K., Geersing, G.J., et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160 (2021), 2247–2259.
Cosmi, B., Management of idiopathic venous thromboembolism. Expert Rev Cardiovasc Ther 14 (2016), 1371–1384.
Kyrle, P.A., Eichinger, S., Clinical scores to predict recurrence risk of venous thromboembolism. Thromb Haemost 108 (2012), 1061–1064.
Streiff, M.B., Predicting the risk of recurrent venous thromboembolism (VTE). J Thromb Thrombolysis 39 (2015), 353–366.
Jara-Palomares, L., Otero, R., Jimenez, D., Carrier, M., Tzoran, I., Brenner, B., et al. Development of a risk prediction score for occult cancer in patients with VTE. Chest 151 (2017), 564–571.
Jara-Palomares, L., Otero, R., Jiménez, D., Praena-Fernández, J.M., Rivas, A., Font, C., et al. Sex differences in patients with occult cancer after venous thromboembolism. Clin Appl Thromb Hemost 24 (2018), 489–495.
Klok, F.A., Ageno, W., Ay, C., Bäck, M., Barco, S., Bertoletti, L., et al. Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. Eur Heart J 43 (2022), 183–189.
Badesch, D.B., Raskob, G.E., Elliott, C.G., Krichman, A.M., Farber, H.W., Frost, A.E., et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 137 (2010), 376–387.
Hoeper, M.M., Huscher, D., Ghofrani, H.A., Delcroix, M., Distler, O., Schweiger, C., et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 168 (2013), 871–880.
Ventetuolo, C.E., Praestgaard, A., Palevsky, H.I., Klinger, J.R., Halpern, S.D., Kawut, S.M., Sex and haemodynamics in pulmonary arterial hypertension. Eur Respir J 43 (2014), 523–530.
Humbert, M., Sitbon, O., Yaïci, A., Montani, D., O'Callaghan, D.S., Jaïs, X., et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 36 (2010), 549–555.
Olsson, K.M., Delcroix, M., Ghofrani, H.A., Tiede, H., Huscher, D., Speich, R., et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 129 (2014), 57–65.
Benza, R.L., Miller, D.P., Gomberg-Maitland, M., Frantz, R.P., Foreman, A.J., Coffey, C.S., et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122 (2010), 164–172.
Chung, L., Liu, J., Parsons, L., Hassoun, P.M., McGoon, M., Badesch, D.B., et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 138 (2010), 1383–1394.
Humbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173 (2006), 1023–1030.
Mukerjee, D., St George, D., Coleiro, B., Knight, C., Denton, C.P., Davar, J., et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62 (2003), 1088–1093.
Chung, L., Farber, H.W., Benza, R., Miller, D.P., Parsons, L., Hassoun, P.M., et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest 146 (2014), 1494–1504.
Zamanian, R.T., Hedlin, H., Greuenwald, P., Wilson, D.M., Segal, J.I., Jorden, M., et al. Features and outcomes of methamphetamine-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 197 (2018), 788–800.
Sitbon, O., Lascoux-Combe, C., Delfraissy, J.F., Yeni, P.G., Raffi, F., De Zuttere, D., et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 177 (2008), 108–113.
Gabler, N.B., French, B., Strom, B.L., Liu, Z., Palevsky, H.I., Taichman, D.B., et al. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest 141 (2012), 20–26.
Mathai, S.C., Hassoun, P.M., Puhan, M.A., Zhou, Y., Wise, R.A., Sex differences in response to tadalafil in pulmonary arterial hypertension. Chest 147 (2015), 188–197.
Ghofrani, H.-A., Galiè, N., Grimminger, F., Grünig, E., Humbert, M., Jing, Z.-C., et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369 (2013), 330–340.
Frantz, R.P., Schilz, R.J., Chakinala, M.M., Badesch, D.B., Frost, A.E., McLaughlin, V.V., et al. Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational study. Chest 147 (2015), 484–494.
Kjellström, B., Sandqvist, A., Hjalmarsson, C., Nisell, M., Näsman, P., Ivarsson, B., Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. ERJ Open Res 6 (2020), 1–10.
Delcroix, M., Torbicki, A., Gopalan, D., Sitbon, O., Klok, F.A., Lang, I., et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J, 2021, 57.
Humbert, M., Kovacs, G., Hoeper, M.M., Badagliacca, R., Berger, R.M.F., Brida, M., et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J, 61, 2023, 2200879.
Humbert, M., Kovacs, G., Hoeper, M.M., Badagliacca, R., Berger, R.M.F., Brida, M., et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 43 (2022), 3618–3731.
Martinez, C., Wallenhorst, C., Teal, S., Cohen, A.T., Peacock, A.J., Incidence and risk factors of chronic thromboembolic pulmonary hypertension following venous thromboembolism, a population-based cohort study in England. Pulm Circ, 8, 2018 2045894018791358.
Chen, T.X., Pudasaini, B., Guo, J., Gong, S.G., Jiang, R., Wang, L., et al. Sex-specific cardiopulmonary exercise testing indices to estimate the severity of inoperable chronic thromboembolic pulmonary hypertension. Int J Chron Obstruct Pulmon Dis 13 (2018), 385–397.
Escribano-Subias, P., Blanco, I., López-Meseguer, M., Lopez-Guarch, C.J., Roman, A., Morales, P., et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J 40 (2012), 596–603.
Yang, Y.L., Yu, Y.Z., Yuan, P., Gong, S.G., Wang, C.Y., Li, Y., et al. Sex differences of hemodynamics during acute vasoreactivity testing to predict the outcomes of chronic thromboembolic pulmonary hypertension. Clin Respir J 14 (2020), 611–621.
Barco, S., Klok, F.A., Konstantinides, S.V., Dartevelle, P., Fadel, E., Jenkins, D., et al. Sex-specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry. J Thromb Haemost 18 (2020), 151–161.
Kallonen, J., Korsholm, K., Bredin, F., Corbascio, M., Andersen, M.J., Ilkjær, L.B., et al. Sex and survival following pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: a Scandinavian observational cohort study. Pulm Circ, 11, 2021 20458940211056014.